Medpace Holdings Inc vs Nvidia Corp — how do they compare? Medpace Holdings Inc trades at $601.71 (market cap $16.90B), while Nvidia Corp trades at $223.94 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 311.8× Medpace Holdings Inc's market cap, and Nvidia Corp pays a 0.46% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | NVDA | |
|---|---|---|
Market Cap | $16.90B | $5.27T |
Sector | Technology | Technology |
52-Week High | $620.59 | $235.75 |
52-Week Low | $393.42 | $165.17 |
Enterprise Value | $16.52B | $5.20T |
Dividend Yield | — | 0.46% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
NVIDIA (NVDA) trades at $223.09, up 2.54% today, with strong technical momentum as the price approaches resistance near $224. The company demonstrates exceptional fundamental strength with 55.84% net profit margins and 114.29% ROE for 2025, supported by consistent earnings beats. Recent news highlights AI leadership driving revenue growth acceleration, though some articles caution about growth sustainability given the stock's massive run-up.
Outlook remains positive with Wall Street consensus target of $325.86 implying 46% upside, though risks include peak AI spending concerns and increased competition. The stock presents a compelling growth opportunity but requires careful risk management given elevated valuations and technical overbought conditions.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →